Enfermedad de Crohn
Estado: ReclutandoA Phase III, multicenter, randomized, double-blind, placebo-controlled study of oral ozanimod as maintenance therapy for moderately to severely active Crohn’s Disease.
Para inscribirte contáctate a:
[email protected]
Principales Criterios de Inclusión:
- Fulfilled the inclusion criteria at time of entry into the induction study and completed the week 12 efficacy assessments of the induction study
- In clinical response and/or clinical remission and/or an average daily stool frequency score ≤ 3 and an average abdominal pain score ≤ 1 with abdominal pain and stool frequency no worse than baseline at Week 12 of the Induction Study
- Laboratorio:Bristol Myers Squibb
- Área Terapéutica:Gastroenterología
- Fase del estudio:III
- Código de Estudio:RPC01-3203
- Ver ensayo en Clinical Trials
Santiago
- CECIM
Santiago
- CTR Estudios SpA
Encuentra tu
ensayo clínico
Elige tu área de interés, patología o región, y accede a tu ensayo clínico.
Buscar ensayos >